QSI — Quantum-Si Incorporated

Is QSI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of October 3, 2026

Quantum-Si Incorporated (QSI) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $1.55.

See all overbought Healthcare stocks →

AI analysis

Quantum-Si’s single-molecule protein sequencing platform represents a potentially transformative technology with a large long-term market opportunity. Near-term prospects remain tethered to instrument adoption, consumable recurring revenue, and successful scale-up of manufacturing and commercial operations. The current macro and investor risk-off backdrop reduces appetite for high-burn device/biotech equities, increasing the chance of dilution if cash runway is insufficient. Key near-term catalysts include meaningful instrument order flow, multi-year collaboration or supply agreements, and demonstrable reproducibility in independent studies. Absent clear adoption signs or partner-led de-risking, price action is likely to remain rangebound with downside vulnerability tied to financing and execution setbacks.

Key factors

  • Proprietary single-molecule protein sequencing technology with potential to address large addressable markets in proteomics and diagnostics.
  • Early commercial traction limited; revenue base remains small with growth dependent on instrument adoption and consumable sales.
  • Balance sheet and cash runway are critical; historical cash burn and likelihood of future dilution are central to near-term outlook.
  • Macro risk-off environment and cooling of device/healthcare IPO activity reduce investor appetite for high-risk instrument/device names.
  • Potential strategic partnerships or large collaboration deals could materially de-risk adoption and provide non-dilutive capital.
  • Competitive landscape in sequencing and proteomics (emerging technologies and entrenched incumbents) creates execution and market-share hurdles.
  • Regulatory, manufacturing scale-up and supply-chain execution will determine speed of commercial ramp and gross-margin outcomes.

Risks

  • High cash burn and limited near-term revenue could force equity raises, diluting existing shareholders.
  • Slow adoption by research and clinical customers; long sales cycles for instruments and uncertain recurring consumable demand.
  • Technical or reproducibility issues in real-world settings could delay broader commercialization.
  • Competition from established sequencing firms and new proteomics entrants offering alternative solutions.
  • Macro-driven funding and capital markets weakness that reduces strategic partner interest or acquisition opportunities.
  • Supply-chain disruptions or manufacturing scale challenges that limit unit delivery and revenue recognition.
  • Policy and payer uncertainty for downstream clinical applications that might slow clinical adoption and reimbursement.

See today's live rating, score and targets

Members see the live hourly rating for QSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.